<HTML><HEAD><META http-equiv="Content-type" content="text/html;charset=UTF-8"></HEAD><BODY><DIV><P><BR>               <BR>               <BR>               <BR>                  WARNING<BR>                  : ASTHMA-RELATED DEATH<BR>               <BR>               <BR>                  <BR>                     L<BR>                     ong-acting beta<BR>                     <BR>                        2<BR>                     <BR>                     -adrenergic agonist<BR>                     s<BR>                      <BR>                     (LABA)<BR>                      increase the risk of asthma-related death.<BR>                      <BR>                     Data from a large placebo-controlled US study that compared the safety of another long-acting beta<BR>                     <BR>                        2<BR>                     <BR>                     -adrenergic agonist (salmeterol) or placebo added to usual asthma therapy showed an increase in asthma-related deaths in patients receiving salmeterol. This finding with salmeterol <BR>                     is considered a class effect of LABA, including<BR>                      indacaterol, the <BR>                     active ingredient in <BR>                     ARCAPTA NEOHALER<BR>                     .  The safety and efficacy of <BR>                     ARCAPTA NEOHALER <BR>                     in patients with asthma have not been established.<BR>                      A<BR>                     RCAPTA NEOHALER<BR>                      is not indicated for the treatment of asthma.<BR>                      [See <BR>                     C<BR>                     ontraindications<BR>                      (4),<BR>                      <BR>                     W<BR>                     arnings and Precautions<BR>                      <BR>                     (5.1)<BR>                     ]<BR>                     .<BR>                  <BR>               <BR>               <BR>               <BR>                  <BR>                     <BR>                        <BR>                           WARNING<BR>                           : ASTHMA-RELATED DEATH<BR>                        <BR>                        <BR>                           See full prescribing information for complete boxed warning<BR>                        <BR>                        <BR>                           <BR>                              L<BR>                              ong<BR>                              -acting beta<BR>                              <BR>                                 2<BR>                              <BR>                              -adrenergic agonist<BR>                              s<BR>                               <BR>                              (LABA) <BR>                              increase the risk of asthma-related death<BR>                               (5.1)<BR>                              .<BR>                               <BR>                           <BR>                           <BR>                              A<BR>                               placebo-controlled study <BR>                              with<BR>                               another long-acting beta<BR>                              <BR>                                 2<BR>                              <BR>                              -adrenergic agonist (salmeterol) showed an increase in asthma-related deaths in patients receiving salmeterol. <BR>                              (5.1)<BR>                           <BR>                           <BR>                              This finding <BR>                              of an increased risk of asthma-related death <BR>                              with salmeterol <BR>                              is considered a class effect of LABA, including<BR>                               indacaterol<BR>                              ,<BR>                               the active <BR>                              ingredient in <BR>                              ARCAPTA NEOHALER<BR>                              .<BR>                               The safety and efficacy of <BR>                              ARCAPTA NEOHALER<BR>                               in patients with asthma have not been established<BR>                              .<BR>                               A<BR>                              RCAPTA NEOHALER<BR>                               is not indicated for the treatment of asthma.<BR>                               <BR>                              (<BR>                              <BR>                                 4, <BR>                              <BR>                                 5.1)<BR>                           <BR>                        <BR>                     <BR>                  <BR>               <BR>            <BR>         </P></DIV></HTML>